Vor Biopharma Inc. (VOR)


+0.22 (+5.15%)
Symbol VOR
Price $4.49
Beta 0.000
Volume Avg. 0.10M
Market Cap 168.817M
Shares () -
52 Week Range 4.01-23.535
1y Target Est -
DCF Unlevered VOR DCF ->
DCF Levered VOR LDCF ->
ROE -26.70% Sell
ROA -25.47% Sell
Operating Margin -
Debt / Equity 20.48% Neutral
P/E -
P/B 0.86 Buy


Consensus EPS

Upgrades & Downgrades

Latest VOR news

NASDAQ Global Select

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.